WDB coco CoTSE:7079 -0.47%78 EBITDA Margin % is 24.58% as of Mar. 2026, which is 16% above its 10-year median of 21.21. GuruFocus rates TSE:7079 with a GF Score™ of 78/100 and a GF Value™ of 円3,452.59 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 668 Healthcare Providers & Services companies, WDB coco Co ranks better than 78.44% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. WDB coco Co's EBITDA for the
six
months ended in Mar. 2026 was 円590 Mil. WDB coco Co's Revenue for the
six
months ended in Mar. 2026 was 円2,401 Mil. Therefore, WDB coco Co's EBITDA margin for the quarter that ended in Mar. 2026 was 24.58%.
WDB coco Co (TSE:7079) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
WDB coco Co EBITDA Margin % Related Terms
WDB coco Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for WDB coco Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7079 vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, WDB coco Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WDB coco Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, WDB coco Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where WDB coco Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WDB coco Co (TSE:7079) has a EBITDA Margin % of 24.58% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on WDB coco Co and its competitors. This is 16% above median its historical median of 21.21. Over the past decade, WDB coco Co's EBITDA Margin % has ranged from 19.16 to 28.42. According to the industry distribution chart, WDB coco Co ranks #144 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 21.6%.
Is WDB coco Co's EBITDA Margin % too high?
WDB coco Co's current EBITDA Margin % of 24.58% is 16% above median its 10-year median of 21.21. Over the past 10 years, this metric has ranged from a low of 19.16 to a high of 28.42. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. WDB coco Co's value of 24.58% is 140.7% above this industry median. Based on the distribution chart, WDB coco Co ranks #144 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, WDB coco Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WDB coco Co's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, WDB coco Co ranks #144 out of 668 companies for EBITDA Margin %. This places WDB coco Co in the top 22% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. WDB coco Co's value of 24.58% is 140.7% above this benchmark. Historically, WDB coco Co's own EBITDA Margin % has ranged from 19.16 to 28.42 over the past decade. While the company's 10-year median is 21.21 vs. the industry median of 10.21, WDB coco Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WDB coco Co's current EBITDA Margin % of 24.58% is 140.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on WDB coco Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WDB coco Co's current EBITDA Margin % is 24.58%, which is 16% above median its own 10-year median of 21.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WDB coco Co stock overvalued right now?
Based on GuruFocus' analysis, WDB coco Co (TSE:7079) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,452.59, compared to a current price of 円2,529.00 — trading 26.8% below its estimated fair value. The current EBITDA Margin % is 24.58%, which is 16% above median its 10-year median of 21.21 and 140.7% above the Healthcare Providers & Services industry median of 10.21. WDB coco Co's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For WDB coco Co (TSE:7079), the current EBITDA Margin % is 24.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WDB coco Co (TSE:7079) Overvalued in 2026?
Based on GuruFocus' analysis, WDB coco Co stock appears to be undervalued.
The current stock price of 円2,529.00 is trading 26.8% below its estimated GF Value™ of 円3,452.59.
GuruFocus considers WDB coco Co to be Modestly Undervalued.
Key valuation signals for TSE:7079:
EBITDA Margin %: 24.58% (16% above median its 10-year median of 21.21)
GF Value™: 円3,452.59 vs. price of 円2,529.00 (26.8% below fair value)
Industry Position: 140.7% above the Healthcare Providers & Services median (#144 of 668)
No single metric tells the full story. See the TSE:7079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WDB coco Co Ltd is a provider of safety information management for the development of pharmaceuticals and medical devices. Its services include business related to safety information management, preparation of materials related to regulatory application, QC-related work, PMS facility contract support related work, clinical research support/monitoring, and temporary staffing. The company provides Contract Research Organization services for all new drug developments, such as monitoring, safety information, data management, and statistical analysis. It provides support for the development of generic drugs, such as bioequivalence studies and biosimilars, clinical research, and physician-led clinical trials.
78GF Score
Get the complete analysis for TSE:7079
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7079 has been successfully added to your 
